Teva Pharmaceutical Industries Limited Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

November 2024 | 50 pages | ID: T5B61BB6EDCBEN
BAC Reports

Abstracts

Teva Pharmaceutical Industries Limited Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Teva Pharmaceutical Industries Limited and its competitors. This provides our Clients with a clear understanding of Teva Pharmaceutical Industries Limited position in the Pharmaceuticals and Biotechnology Industry.

• The report contains detailed information about Teva Pharmaceutical Industries Limited that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• Another part of the report is a SWOT-analysis carried out for Teva Pharmaceutical Industries Limited. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
• The Teva Pharmaceutical Industries Limited financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
• In the part that describes Teva Pharmaceutical Industries Limited competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Teva Pharmaceutical Industries Limited business.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited, a global pharmaceutical company, engages in the development, production, and marketing of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide. Its global presence covers North America, Europe, Latin America, Asia, and Israel.

Product Offerings

GENERIC PRODUCTS

The company manufactures and sells generic pharmaceutical products in various dosage forms, including tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The company also focuses on sale of generic injectable products to hospitals, clinics, and other institutional channels in the U.S.; Europe; Latin America; and central and eastern Europe.

North America

The United States: The company’s principal U.S. subsidiary, Teva Pharmaceuticals USA, Inc., is a generic drug company in the U.S. The company markets approximately 400 generic products in approximately 1,300 dosage strengths and packaging sizes. It also has the capability to formulate, fill, label, and package finished dosage forms of injectable pharmaceutical products. The company, with the acquisition of Barr Pharmaceuticals Inc., has approximately 599 million prescriptions.

Collaborations: The company has entered into a marketing and product development agreement with Biovail Corporation that provided it with U.S. marketing rights for certain of Biovail’s pipeline of controlled-release generic versions of brands. Under this agreement, it markets generic versions of Cardizem CD (diltiazem HCl), Adalat CC (nifedipine), and Procardia XL (nifedipine XL) in the U.S. The company also has entered into a long-term supply agreement under which Biovail purchases active pharmaceutical ingredients from the company.

The company has entered into a strategic alliance agreement for 12 controlled-release generic pharmaceutical products with Impax Laboratories, Inc. The agreement grants it exclusive U.S. marketing rights and an option to acquire marketing rights in the rest of North America, Latin America, Europe, and Israel. Under this agreement, the company markets generic versions of Wellbutrin SR (bupropion) tablets, Zyban (bupropion) tablets, Ditropan XL (oxybutynin), and Wellbutrin XL (bupropion XL) tablets.

Canada: Through Teva Canada Ltd., its Canadian subsidiary, the company manufactures and markets generic prescription pharmaceuticals in Canada. It has a product portfolio that includes 217 generic products in 765 dosage forms and packaging sizes. In 2009, the company launched generic equivalents of the following branded products: MS Contin (morphine sulfate) (15mg and 30mg), Inhibace Plus (cilazapril/HCTZ), Duragesic (fentanyl transdermal patch), Didrocal (etidronate cal), Levaquin (levofloxacin), Norvasc (amlodipine), Evista (raloxifene), Pharmorubicin (epirubicin HCl injection), Exelon (rivastigmine), Vasotec (enalapril maleate), Prevacid (lansoprazole DR), and Amerge (naratriptan). The company’s sales force in Canada markets generic products to retail chains, retail buying groups and independent pharmacies reaching approximately 7,500 outlets.

Europe

Teva Europe is a generic pharmaceutical company in Europe, with direct operations in 26 EU member states, as well as Norway and Switzerland. In 2009, the company launched 19 generic versions of the following branded products in Europe: Vancenase (beclomethasone dipropionate), Losec/Prilosec (omeprazole), Ventolin (salbutamol sulfate), Neurontin (gabapentin), Eloxatin (oxaliplatin), Casodex (bicalutamide), Rhinocort (budesonide), Effexor (venlafaxine HCl), Protonix (pantoprazole sodium), Temesta (lorazepam), Dostinex /Cabaser (cabergoline), Camptosar (irinotecan HCl), Neupogen (filgrastim), Gemzar (gemcitabine HCl), Femara (letrozole), Plavix (clopidogrel hydrobromide), and Hyzaar (losartan potassium/HCTZ). As of December 31, 2009, the company had received 1,035 generic approvals in Europe relating to 164 compounds in 324 formulations, including 12 European Commission approvals valid in all EU member states.

Czech Republic: The company is a generic pharmaceutical company in the Czech Republic, with a portfolio of 153

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. TEVA PHARMACEUTICAL INDUSTRIES LIMITED COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. TEVA PHARMACEUTICAL INDUSTRIES LIMITED BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. TEVA PHARMACEUTICAL INDUSTRIES LIMITED SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. TEVA PHARMACEUTICAL INDUSTRIES LIMITED FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. TEVA PHARMACEUTICAL INDUSTRIES LIMITED COMPETITORS AND INDUSTRY ANALYSIS

5.1. Teva Pharmaceutical Industries Limited Direct Competitors
5.2. Comparison of Teva Pharmaceutical Industries Limited and Direct Competitors Financial Ratios
5.3. Comparison of Teva Pharmaceutical Industries Limited and Direct Competitors Stock Charts
5.4. Teva Pharmaceutical Industries Limited Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Teva Pharmaceutical Industries Limited Industry Position Analysis

6. TEVA PHARMACEUTICAL INDUSTRIES LIMITED NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED EXPERTS REVIEW¹

7.1. Experts Consensus
7.2. Experts Revisions

8. TEVA PHARMACEUTICAL INDUSTRIES LIMITED ENHANCED SWOT ANALYSIS²

9. ISRAEL PESTEL ANALYSIS²

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. TEVA PHARMACEUTICAL INDUSTRIES LIMITED PORTER FIVE FORCES ANALYSIS²

12. TEVA PHARMACEUTICAL INDUSTRIES LIMITED VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Teva Pharmaceutical Industries Limited Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Teva Pharmaceutical Industries Limited 1-year Stock Charts
Teva Pharmaceutical Industries Limited 5-year Stock Charts
Teva Pharmaceutical Industries Limited vs. Main Indexes 1-year Stock Chart
Teva Pharmaceutical Industries Limited vs. Direct Competitors 1-year Stock Charts
Teva Pharmaceutical Industries Limited Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

Teva Pharmaceutical Industries Limited Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Teva Pharmaceutical Industries Limited Key Executives
Teva Pharmaceutical Industries Limited Major Shareholders
Teva Pharmaceutical Industries Limited History
Teva Pharmaceutical Industries Limited Products
Revenues by Segment
Revenues by Region
Teva Pharmaceutical Industries Limited Offices and Representations
Teva Pharmaceutical Industries Limited SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Teva Pharmaceutical Industries Limited Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Teva Pharmaceutical Industries Limited Capital Market Snapshot
Teva Pharmaceutical Industries Limited Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Teva Pharmaceutical Industries Limited Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Teva Pharmaceutical Industries Limited Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

• How to use the strengths to take advantage of the opportunities?
• How to use the strengths to reduce likelihood and impact of the threats?
• How to overcome the weaknesses that obstruct taking advantage of the opportunities?
• How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

• Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
• Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
• Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
• Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
• Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
• Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

1. What composes a threat of substitute products and services?
2. Is there a threat of new competitors entering the market?
3. What is the intensity of competitive rivalry?
4. How big is the bargaining power of buyers?
5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

• Tangible resources
  • Financial
  • Physical
  • Technological
  • Organizational
• Intangible resources
  • Human
  • Innovation and Creativity
  • Reputation
• Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

• Valuable?
• Rare?
• Costly to imitate?
• Organized properly?